An observational study in Adnexal Mass, Germline BRCA1 Gene Mutation and Germline BRCA2 Gene Mutation, sponsored by Aspira Women's Health. Terminated at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.
Sponsored by Aspira Women's Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Hereditary Breast and Ovarian Cancer Syndrome · United States.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, this one is the 7th largest by enrollment of the 12 observational ones that give a count, is one of 4 that started in 2020, is one of 12 observational ones, and was the 28th registered.
62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.
Browse Hereditary Breast and Ovarian Cancer Syndrome studies →7 of the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 35+ · Women only
Georgetown University · Sites in United States
Ages 18–74 · Women only
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
University of Kansas Medical Center · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is below the median of 850 across 18 observational studies indexed under Hereditary Breast and Ovarian Cancer Syndrome.
Median enrollment 157 across the 23 interventional studies, 440 across the 12 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 35 have an industry lead sponsor. The 10 most frequent:
Aspira Women's Health is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Aspira Women's Health has 1 study filed under Hereditary Breast and Ovarian Cancer Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02302742University of Kansas Medical CenterTriple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry | 2026-12 |
| NCT06892275Georgetown UniversityThe FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI | 2027-06 |
| NCT05677048M.D. Anderson Cancer CenterFeasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.
Women with or without a pelvic mass.
Key inclusion criteria:
Cohort A specific inclusion criteria:
Cohort B specific inclusion criteria:
Cohort C specific inclusion criteria:
Exclusion Criteria:
Women with a pelvic mass, symptomatic or asymptomatic.
Other: OVA360
Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
Other: OVA360
Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
Other: OVA360
Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
OVA360
Identify the molecular key driver of Ovarian cancer and develop a diagnostic test for early Ovarian cancer detection
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2020 to primary completion in Dec 2023, 43 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hereditary Breast and Ovarian Cancer Syndrome →
Aspira Women's Health